QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Access Pharmaceuticals, Inc. (ACCP.OB) Presenting Posters at the Innovations in Cancer Prevention and Research Conference 0 comments
    Nov 17, 2010 5:39 PM | about stocks: ACCP

    Access Pharmaceuticals, Inc. will be displaying posters on its novel developments in drug delivery platforms for cancer therapy this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX. The Inaugural Conference is being held November 17-19, 2010 and is hosted by the rapidly-growing Cancer Prevention and Research Institute of Texas whose mission is to “create and support infrastructure in Texas that accelerates the movement of new cancer drugs, diagnostics, and therapies from the laboratory to the patient.”

    Access Pharmaceuticals will be presenting two posters at the event. Poster “Vitamin B-12 Nanoparticles for the Targeted Delivery of RNAi Therapeutics” will showcase Access’ CobaCyte (formerly called “Cobalamin”) for RNAi. This oral drug delivery innovation is showing strong promise because of its ability to allow drug molecules that are attached to a B12 analog to be absorbed through the walls of the intestine, including large molecules such as insulin and many hormones, which may prove to be very beneficial in cancer therapy.

    The second poster, titled, “Preclinical and Clinical Studies of ProLindac: A Novel Polymer Prodrug of DACH Platinum”, summarizes the advantages of ProLindac, the Company’s second generation DACH Platinum. ProLindac has recently been in industry news as Access Pharmaceuticals has begun an open-label, Phase II clinical study of ProLindac in combination with paclitaxel in platinum-sensitive ovarian cancer patients. Other newly compiled safety and efficacy data on ProLindac from its Phase II monotherapy clinical study of ProLindac™ in late-stage, heavily pretreated ovarian cancer patients has shown very promising results in disease stabilization and Ca-125 reduction.

    More information on Access Pharmaceuticals and its pipeline can be found on the company’s website at accesspharma.com

    More information on the event can be found at www.cpritfoundation.org/events/upcoming-...

    Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

    Disclosure: no positions

    Stocks: ACCP
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.